Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals.
Shikuma CM, Ribaudo HJ, Zheng Y, Gulick RM, Meyer WA, Tashima KT, Bastow B, Kuritzkes DR, Glesby MJ; AIDS Clinical Trials Group A5095 Study Team. Shikuma CM, et al. Among authors: meyer wa. AIDS Res Hum Retroviruses. 2011 May;27(5):461-8. doi: 10.1089/aid.2010.0154. Epub 2010 Nov 23. AIDS Res Hum Retroviruses. 2011. PMID: 20863238 Free PMC article. Clinical Trial.
Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).
Shikuma CM, Yang Y, Glesby MJ, Meyer WA 3rd, Tashima KT, Ribaudo HJ, Webb N, Bastow B, Kuritzkes DR, Gulick RM. Shikuma CM, et al. Among authors: meyer wa 3rd. J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):540-50. doi: 10.1097/QAI.0b013e318031d5a0. J Acquir Immune Defic Syndr. 2007. PMID: 17245230 Clinical Trial.
Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.
Kuritzkes DR, Ribaudo HJ, Squires KE, Koletar SL, Santana J, Riddler SA, Reichman R, Shikuma C, Meyer WA 3rd, Klingman KL, Gulick RM; ACTG A5166s Protocol Team. Kuritzkes DR, et al. Among authors: meyer wa 3rd. J Infect Dis. 2007 Apr 15;195(8):1169-76. doi: 10.1086/512619. Epub 2007 Mar 6. J Infect Dis. 2007. PMID: 17357053 Clinical Trial.
Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.
Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA 3rd, Shikuma C, Johnson VA, Fiscus SA, D'Aquila RT, Schackman BR, Acosta EP, Gulick RM. Kuritzkes DR, et al. Among authors: meyer wa 3rd. J Infect Dis. 2008 Mar 15;197(6):867-70. doi: 10.1086/528802. J Infect Dis. 2008. PMID: 18269317
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.
Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, Giguel F, Meyer WA 3rd, Johnson VA, Fiscus SA, D'Aquila RT, Gulick RM, Kuritzkes DR; AIDS Clinical Trials Group (ACTG) A5095 Study Team. Paredes R, et al. Among authors: meyer wa 3rd. J Infect Dis. 2010 Mar;201(5):662-71. doi: 10.1086/650543. J Infect Dis. 2010. PMID: 20102271 Free PMC article.
Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.
Mugavero MJ, May M, Ribaudo HJ, Gulick RM, Riddler SA, Haubrich R, Napravnik S, Abgrall S, Phillips A, Harris R, Gill MJ, de Wolf F, Hogg R, Günthard HF, Chêne G, D'Arminio Monforte A, Guest JL, Smith C, Murillas J, Berenguer J, Wyen C, Domingo P, Kitahata MM, Sterne JA, Saag MS; AIDS Clinical Trial Group DACS 241 Team; AIDS Clinical Trial Group Study 5095 Team; AIDS Clinical Trial Group Study 5142 team; Antiretroviral Cohort Collaboration. Mugavero MJ, et al. J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):253-60. doi: 10.1097/QAI.0b013e318230372e. J Acquir Immune Defic Syndr. 2011. PMID: 21857357 Free PMC article. Clinical Trial.
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA 3rd, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR; AIDS Clinical Trials Group Study A5095 Team. Gulick RM, et al. Among authors: meyer wa 3rd. N Engl J Med. 2004 Apr 29;350(18):1850-61. doi: 10.1056/NEJMoa031772. N Engl J Med. 2004. PMID: 15115831 Free article. Clinical Trial.
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA 3rd, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR; AIDS Clinical Trials Group (ACTG) A5095 Study Team. Gulick RM, et al. Among authors: meyer wa 3rd. JAMA. 2006 Aug 16;296(7):769-81. doi: 10.1001/jama.296.7.769. JAMA. 2006. PMID: 16905783 Clinical Trial.
Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States.
Adeyemi OM, Agniel D, French AL, Tien PC, Weber K, Glesby MJ, Villacres MC, Sharma A, Merenstein D, Golub ET, Meyer W, Cohen M. Adeyemi OM, et al. J Acquir Immune Defic Syndr. 2011 Jul 1;57(3):197-204. doi: 10.1097/QAI.0b013e31821ae418. J Acquir Immune Defic Syndr. 2011. PMID: 21471818 Free PMC article.
Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy.
Wohl DA, McComsey G, Tebas P, Brown TT, Glesby MJ, Reeds D, Shikuma C, Mulligan K, Dube M, Wininger D, Huang J, Revuelta M, Currier J, Swindells S, Fichtenbaum C, Basar M, Tungsiripat M, Meyer W, Weihe J, Wanke C. Wohl DA, et al. Clin Infect Dis. 2006 Sep 1;43(5):645-53. doi: 10.1086/507333. Epub 2006 Jul 27. Clin Infect Dis. 2006. PMID: 16886161 Review.
120 results